A systematic review and meta-analysis of the risk of diarrhea associated with vandetanib treatment in carcinoma patients

References

• CarlomagnoFVitaglianoDGuidaTZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinasesCancer Res2002627284729012499271
   PubMed Web of Science ®Google Scholar
• WedgeSROgilvieDJDukesMZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administrationCancer Res2002624645465512183421
   PubMed Web of Science ®Google Scholar
• MorabitoAPiccirilloMCCostanzoRVandetanib: An overview of its clinical development in NSCLC and other tumorsDrugs Today (Barc)20104668369820967300
   PubMed Web of Science ®Google Scholar
• NaumovGNNilssonMBCasconeTCombined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistanceClin Cancer Res2009153484349419447865
   PubMed Web of Science ®Google Scholar
• MorabitoAPiccirilloMCFalasconiFVandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directionsOncologist20091437839019349511
   PubMed Web of Science ®Google Scholar
• LodishMBStratakisCARET oncogene in MEN2, MEN2B, MTC and other forms of thyroid cancerExpert Rev Anticancer Ther2008862563218402529
   PubMed Web of Science ®Google Scholar
• SimMWCohenMSThe discovery and development of vandetanib for the treatment of thyroid cancerExpert Opin Drug Discov2014910511424299515
   PubMed Web of Science ®Google Scholar
• GrabowskiPBriestFBaumRPVandetanib therapy in medullary thyroid cancerDrugs Today (Barc)20124872373323170308
   PubMed Web of Science ®Google Scholar
• RosenACWuSDamseAShermanELacoutureMERisk of rash in cancer patients treated with vandetanib: systematic review and meta-analysisJ Clin Endocrinol Metab2012971125113322378813
   PubMed Web of Science ®Google Scholar
• QiWXShenZLinFIncidence and risk of hypertension with vandetanib in cancer patients: a systematic review and meta-analysis of clinical trialsBr J Clin Pharmacol20137591993022882307
   PubMed Web of Science ®Google Scholar
• YangJCReguartNBarinoffJDiarrhea associated with afatinib: an oral ErbB family blockerExpert Rev Anticancer Ther20131372973623506556
   PubMed Web of Science ®Google Scholar
• AhnJSLeeKHSunJMA randomized, phase II study of vandetanib maintenance for advanced or metastatic non-small-cell lung cancer following first-line platinum-doublet chemotherapyLung Cancer20138245546024075125
   PubMed Web of Science ®Google Scholar
• WellsSAJrRobinsonBGGagelRFVandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trialJ Clin Oncol20123013414122025146
   PubMed Web of Science ®Google Scholar
• KreislTNMcNeillKASulJIwamotoFMShihJFineHAA phase I/II trial of vandetanib for patients with recurrent malignant gliomaNeuro Oncol2012141519152623099652
   PubMed Web of Science ®Google Scholar
• LeboulleuxSBastholtLKrauseTVandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trialLancet Oncol20121389790522898678
   PubMed Web of Science ®Google Scholar
• LeeJSHirshVParkKVandetanib Versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR)J Clin Oncol2012301114112122370318
   PubMed Web of Science ®Google Scholar
• HsuCYangTSHuoTIVandetanib in patients with inoperable hepatocellular carcinoma: a phase II, randomized, double-blind, placebo-controlled studyJ Hepatol2012561097110322245891
   PubMed Web of Science ®Google Scholar
• NataleRBThongprasertSGrecoFAPhase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancerJ Clin Oncol2011291059106621282542
   PubMed Web of Science ®Google Scholar
• WellsSAJrGosnellJEGagelRFVandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancerJ Clin Oncol20102876777220065189
   PubMed Web of Science ®Google Scholar
• NataleRBBodkinDGovindanRVandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase ii studyJ Clin Oncol2009272523252919332730
   PubMed Web of Science ®Google Scholar
• KiuraKNakagawaKShinkaiTA randomized, double-blind, phase II a dose-finding study of Vandetanib (ZD6474) in Japanese patients with non-small cell lung cancerJ Thorac Oncol2008338639318379357
   PubMed Web of Science ®Google Scholar
• HeymachJVPaz-AresLDe BraudFRandomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancerJ Clin Oncol2008265407541518936474
   PubMed Web of Science ®Google Scholar
• ArnoldAMSeymourLSmylieMNational Cancer Institute of Canada Clinical Trials Group Study BR.20Phase II study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy: National Cancer Institute of Canada Clinical Trials Group Study BR.20J Clin Oncol2007254278428417878480
   PubMed Web of Science ®Google Scholar
• MillerKDTrigoJMWheelerCA multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancerClin Cancer Res2005113369337615867237
   PubMed Web of Science ®Google Scholar
• EltingLSChangYCParelkarPMucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO)Risk of oral and gastrointestinal mucosal injury among patients receiving selected targeted agents: a meta-analysisSupport Care Cancer2013213243325423636648
   PubMed Web of Science ®Google Scholar
• UribeJMGelbmannCMTraynor-KaplanAEBarrettKEEpidermal growth factor inhibits Ca(2+)-dependent Cl- transport in T84 human colonic epithelial cellsAm J Physiol1996271C914C9228843722
   PubMed Web of Science ®Google Scholar
• Al-DasooqiNGibsonRBowenJKeefeDHER2 targeted therapies for cancer and the gastrointestinal tractCurr Drug Targets20091053754219519356
   PubMed Web of Science ®Google Scholar
• HirshVBlaisNBurkesRVermaSCroitoruKManagement of diarrhea induced by epidermal growth factor receptor tyrosine kinase inhibitorsCurr Oncol20142132933625489260
   PubMed Web of Science ®Google Scholar
• GrandeEKreisslMCFilettiSVandetanib in advanced medullary thyroid cancer: review of adverse event management strategiesAdv Ther20133094596624249433
   PubMed Web of Science ®Google Scholar
• HirshVManaging treatment-related adverse events associated with egfr tyrosine kinase inhibitors in advanced non-small-cell lung cancerCurr Oncol20111812613821655159
   PubMed Web of Science ®Google Scholar
• CohenEEHalpernABKaszaKKocherginskyMWilliamsRVokesEEFactors associated with clinical benefit from epidermal growth factor receptor inhibitors in recurrent and metastatic squamous cell carcinoma of the head and neckOral Oncol200945e155e16019586795
   PubMed Web of Science ®Google Scholar
• ZhengYWangFWuGThe relationship between the adverse events and efficacy of sorafenib in patients with metastatic renal cell carcinoma: a multicenter retrospective study from Northwest ChinaMedicine (Baltimore)201594e222226656362
   PubMed Web of Science ®Google Scholar
• ZhangHLQinXJWangHKClinicopathological and prognostic factors for long-term survival in Chinese patients with metastatic renal cell carcinoma treated with sorafenib: a single-center retrospective studyOncotarget20156368703688326472104
   PubMedGoogle Scholar
• BettingerDSchultheissMKnuppelEThimmeRBlumHESpangenbergHCDiarrhea predicts a positive response to sorafenib in patients with advanced hepatocellular carcinomaHepatology20125678979022307848
   PubMed Web of Science ®Google Scholar